2-(benzylthio)-5-(4-methoxyphenyl)-1,3,4-oxadiazole | 197371-67-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(benzylthio)-5-(4-methoxyphenyl)-1,3,4-oxadiazole
• 英文别名: 2-(Benzylsulfanyl)-5-(4-methoxyphenyl)-1,3,4-oxadiazole；2-benzylsulfanyl-5-(4-methoxyphenyl)-1,3,4-oxadiazole
• CAS: 197371-67-8
• 化学式: C₁₆H₁₄N₂O₂S
• 分子量: 298.365
• InChiKey: IHFLZRDDOQFEPG-UHFFFAOYSA-N

物化性质

• 沸点：
  466.8±55.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  73.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  对甲氧基苯甲酰肼 在 三乙胺 、 sodium hydroxide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 2-(benzylthio)-5-(4-methoxyphenyl)-1,3,4-oxadiazole
  参考文献：
  名称：

  Structure-based optimization of oxadiazole-based GSK-3 inhibitors

  摘要：

  Inhibition of glycogen synthase kinase-3 (GSK-3) induces neuroprotective effects, e.g. decreases beta-amyloid production and reduces tau hyperphosphorylation, which are both associated with Alzheimer's disease (AD). The two isoforms of GSK-3 in mammalians are GSK-3 alpha and beta, which share 98% homology in their catalytic domains. We investigated GSK-3 inhibitors based on 2 different scaffolds in order to elucidate the demands of the ATP-binding pocket [1]. Particularly, the oxadiazole scaffold provided potent and selective GSK-3 inhibitors. For example, the most potent inhibitor of the present series, the acetamide 26d, is characterized by an IC50 of 2 nM for GSK-3 alpha and 17 nM for GSK-3 beta. In addition, the benzodioxane 8g showed up to 27-fold selectivity for GSK-3 alpha over GSK-3 beta, with an IC50 of 35 nM for GSK-3 alpha. Two GSK-3 inhibitors were further profiled for efficacy and toxicity in the wild-type (wt) zebrafish embryo assay to evaluate simultaneously permeability and safety. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.06.006

文献信息

• COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS
  申请人：THE BROAD INSTITUTE, INC.

  公开号：US20160031870A1

  公开（公告）日：2016-02-04

  Disclosed are compounds that can be used for treating tuberculosis.

  本发明涉及用于治疗结核病的化合物。
• Compounds for the treatment of tuberculosis
  申请人：THE BROAD INSTITUTE, INC.

  公开号：US10301294B2

  公开（公告）日：2019-05-28

  Disclosed are compounds that can be used for treating tuberculosis.

  所公开的是可用于治疗结核病的化合物。
• [EN] COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE LA TUBERCULOSE
  申请人：BROAD INST INC

  公开号：WO2014165090A1

  公开（公告）日：2014-10-09

  Disclosed are compounds that can be used for treating tuberculosis.
• Structure-based optimization of oxadiazole-based GSK-3 inhibitors
  作者：Fabio Lo Monte、Thomas Kramer、Jiamin Gu、Martin Brodrecht、Johannes Pilakowski、Ana Fuertes、Juan Manuel Dominguez、Batya Plotkin、Hagit Eldar-Finkelman、Boris Schmidt

  DOI：10.1016/j.ejmech.2012.06.006

  日期：2013.3

  Inhibition of glycogen synthase kinase-3 (GSK-3) induces neuroprotective effects, e.g. decreases beta-amyloid production and reduces tau hyperphosphorylation, which are both associated with Alzheimer's disease (AD). The two isoforms of GSK-3 in mammalians are GSK-3 alpha and beta, which share 98% homology in their catalytic domains. We investigated GSK-3 inhibitors based on 2 different scaffolds in order to elucidate the demands of the ATP-binding pocket [1]. Particularly, the oxadiazole scaffold provided potent and selective GSK-3 inhibitors. For example, the most potent inhibitor of the present series, the acetamide 26d, is characterized by an IC50 of 2 nM for GSK-3 alpha and 17 nM for GSK-3 beta. In addition, the benzodioxane 8g showed up to 27-fold selectivity for GSK-3 alpha over GSK-3 beta, with an IC50 of 35 nM for GSK-3 alpha. Two GSK-3 inhibitors were further profiled for efficacy and toxicity in the wild-type (wt) zebrafish embryo assay to evaluate simultaneously permeability and safety. (C) 2012 Elsevier Masson SAS. All rights reserved.